1-6 of 6
Wendy L. See
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi
Journal: Blood
Blood (2023) 142 (Supplement 1): 1582.
https://doi.org/10.1182/blood-2023-187651
Published: 2023
Journal Articles

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2 -Mutated Acute Myeloid Leukemia (AML)

Alberto Risueño, Wendy L. See, Courtney D. DiNardo, Hartmut Döhner, Eytan Stein, Amir T. Fathi, Paresh Vyas, Lynn Quek, Thomas Prebet, Anita K. Gandhi, Maroof Hasan
Journal: Blood
Blood (2022) 140 (Supplement 1): 732–734.
https://doi.org/10.1182/blood-2022-158967
Published: 2022
Journal Articles

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine

Clinical Trials & Observations
Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R. Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes
Journal: Blood
Blood (2022) 140 (15): 1674–1685.
https://doi.org/10.1182/blood.2022016293
Published: 2022
Includes: Supplemental data
Journal Articles

Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance

Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther Chan, Anjan Thakurta, C.L. Beach, Daniel Lopes de Menezes
Journal: Blood
Blood (2021) 138 (Supplement 1): 804.
https://doi.org/10.1182/blood-2021-147465
Published: 2021
Journal Articles

CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta, Daniel Lopes de Menezes, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-137606
Published: 2020
Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Uwe Platzbecker, Diana Dunshee, Rami S. Komrokji, MD, Ghulam J. Mufti, Guillermo Garcia-Manero, MD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Mikkael A. Sekeres, MD MS, Wendy L. See, Kevin Tsai, Alberto Risueño, Jianglin Ma, Martin Schwickart, Anita Rampersad, Jennie Zhang, Abderrahmane Laadem, Daniel Menezes, Kyle MacBeth, PhD, Peter G. Linde, Joseph G. Reynolds, PhD, Alan F. List, MD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2999.
https://doi.org/10.1182/blood-2019-123655
Published: 2019